Effect of Sildenafil for Sustained PAH After MV Surgery (SUPERIOR Trial) (SUPERIOR)
Effect of Sildenafil for the Treatment of Sustained Pulmonary Artery Hypertension After Corrected Mitral Valve Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- New York Heart Association Functional class (NYHA Fc) ≥ 2 dyspnea which was sustained till one year after the previous mitral valve surgery (repair or replacement)
- TR Vmax ≥ 3.5m/s by echocardiography
- Normal left ventricle ejection fraction (EF ≥ 50%)
- Pulmonary vascular resistance ≥ 3 Wood Unit or diastolic pressure gradient ≥ 7mmHg by cardiac catheterization
Exclusion Criteria:
- Other valve disease more than moderate degree (ex. aortic stenosis, aortic regurgitation)
- Liver cirrhosis
- Chronic renal failure with serum creatinine ≥ 1.7mg/dL
- Lung disease (ex. chronic obstructive pulmonary disease, Asthma)
- Thyroid dysfunction
- Other causes which can lead to pulmonary hypertension
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Sildenafil
Sildenafil 20mg tid for six months (* consider open-label extension study for 1 year)
|
Other Names:
|
|
Placebo Comparator: Placebo
Placebo tablets do not contain an active ingredient but are identical in shape with each active tablet of Sildenafil
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of Six Minutes Walk Distance
Time Frame: baseline and six months
|
unit of measure : meter (m)
|
baseline and six months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Borg dyspnea score
Time Frame: six months
|
six months
|
|
|
Exercise capacity by cardiopulmonary exercise test
Time Frame: six months
|
six months
|
|
|
Fractional area change of right ventricle measured by echocardiography
Time Frame: six months
|
unit of measure : percent (%)
|
six months
|
|
Pulmonary vascular resistance (PVR) measured by cardiac catheterization
Time Frame: six months
|
unit of measure : wood unit (WU)
|
six months
|
|
Systolic pulmonary artery pressure measured by cardiac catheterization
Time Frame: six months
|
unit of measure : pressure (mmHg)
|
six months
|
|
Mean pulmonary artery pressure measured by cardiac catheterization
Time Frame: six months
|
unit of measure : pressure (mmHg)
|
six months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jong-Min Song, Asan Medical Center
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Hypertension
- Hypertension, Pulmonary
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Urological Agents
- Enzyme Inhibitors
- Phosphodiesterase Inhibitors
- Phosphodiesterase 5 Inhibitors
- Sildenafil Citrate
Other Study ID Numbers
Other Study ID Numbers
- MVsurgery_PAH
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.